Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics Presents New Cemsidomide Biomarker Data at 23rd IMS Annual Meeting

Neutral Impact 3 of 5 other Written later

C4 Therapeutics presented new biomarker data from its Phase 1 cemsidomide trial with dexamethasone and preliminary data from the first two patients in its Phase 1b trial with elranatamab at the 23rd International Myeloma Society Annual Meeting. The filing also reports that the safety data review committee declared the 75 µg dose level safe in combination with elranatamab, and the trial is advancing to a dose escalation cohort at 100 µg and an expansion cohort at 75 µg. The filing does not include financial results, and the company expects data from all Phase 1b cohorts in mid-2027.

Key points

  • Phase 1 trial with dexamethasone included 62 heavily pre-treated RRMM patients across once-daily dose levels
  • Biomarker data from the first two Phase 1b patients is based on information as of June 22, 2026
  • Safety data review committee declared the 75 µg dose safe with elranatamab after a six-patient first safety cohort
  • Data from all Phase 1b cohorts are expected in mid-2027

The filing

CompanyC4 Therapeutics, Inc. (CCCC)
Form8-K, current report
Filed with the SECSep 25, 2026, 7:04 AM ET
Accession number0001628280-26-063497

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.